United States· US:85043-030_b8da8614-75a8-453c-be31-0568da16a3b9
Vabrinty
A leuprorelin product containing leuprolide acetate, registered in United States by URONOVA PHARMACEUTICALS, INC.. The same ATC class is registered in 13 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Leuprorelin is registered in 13 of 19 countries.
Countries holding a registration under ATC L02AE02 (leuprorelin), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 9 of them publish a price we can compare per daily dose
Leuprorelin · ATC L02AE02
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Statesprice
Price per daily dose
What a daily dose of leuprorelin costs, country by country.
Normalised to the WHO defined daily dose (1 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Leuprorelin · price per daily dose (1 mg)
USD · FX 28 Sept 2026
- CH Switzerland$34.21
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- Leuprolide acetate
- Manufacturer
- URONOVA PHARMACEUTICALS, INC.
- Country
- United States (US)
- ATC code
- L02AE02
- ATC class
- Leuprorelin
- Defined daily dose
- 1 mg, P
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 12, 2026
Packs & prices · 1
- ndc1185043030031 SYRINGE in 1 CARTON (85043-030-03) / .5 mL in 1 SYRINGE
Regulatory notes
Interactions
320 interactions on record for leuprorelin.
Graded by severity as the source publishes them — 69 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Leuprorelin · interactions on record
320 records
- 69 severe
- 248 moderate
- 3 minor
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- DolasetronA04AA04severe
- QuinidineC01BA01severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Leuprorelin in 17 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NetherlandsCAMCEVI 21 mg suspensie voor injectie met verlengde afgifteAccord Healthcare S.L.U.
- FinlandCAMCEVIAccord Healthcare S.L.U.
- United KingdomCamcevi 42mg prolonged-release suspension for injection pre-filled syringesAccord-UK Ltd
- SwedenCAMCEVI 21 mg Injektionsvätska, depotsuspensionAccord Healthcare S.L.U.
- GermanyEligardPb Pharma Gmbh
- IrelandCAMCEVI 21 mg prolonged-release suspension for injectionAccord Healthcare S.L.U.
- CzechiaCAMCEVIAccord Healthcare S.L.U., Barcelona
- SpainCAMCEVI 42 MG SUSPENSION INYECTABLE DE LIBERACION PROLONGADAAccord Healthcare S.L.U.
Authorised across Europe · EMA
The same active substance is authorised in 31 EEA countries. Names it is sold under:
- Austria · Eligard Depot, Enantone Monats-Depot
- Belgium · Depo-Eligard
- Bulgaria · Елигард, Лутрат Депо
- Cyprus · Eligard
- Czechia · Eligard, Leptoprol
- Germany · Eligard, Enantone Monats-Depot
- Denmark · Eligard, Leuprorelin Sandoz
- Estonia · Eligard
- Spain · Eligard Semestral, Eligard Trimestral
- Finland · Eligard, Enanton Depot Dual
- France · Eligard, Enantone Lp
- United Kingdom (Northern Ireland) · Prostap 3 Dcs, Prostap Pd Dcs
- Greece · Deplanda, Elityran
- Croatia · Eligard, Lerin
- Hungary · Eligard, Leuprorelin Pharmacenter
- Ireland · Eligard, Leuprex 3
- Iceland · Camcevi, Eligard
- Italy · Eligard, Enantone
- Liechtenstein · Camcevi
- Lithuania · Eligard
- Luxembourg · Depo-Eligard, Leugon
- Latvia · Eligard, Leptoprol
- Malta · Deplanda
- Netherlands · Eligard, Leuproreline Sandoz
- Norway · Camcevi, Eligard
- Poland · Eligard, Leuprostin
- Portugal · Eligard, Lutrate Depot
- Romania · Eligard, Leptoprol
- Sweden · Eligard, Enanton Depot Dual
- Slovenia · Eligard, Leptoprol
- Slovakia · Eligard, Leuprorelin Sandoz
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/abce75c1-9251-4d26-bd00-82c2e8bf01b2 GET /v1/drugs/abce75c1-9251-4d26-bd00-82c2e8bf01b2?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unii": {
"unii": "37JNS02E7V",
"rxcui": "203217",
"inchikey": "RGLRXNKKBLIBQS-XNHQSDQCSA-N",
"display_name": "LEUPROLIDE ACETATE",
"substance_type": "chemical",
"ingredient_type": "INGREDIENT SUBSTANCE"
},
"route": "SUBCUTANEOUS",
"livertox": {
"summary": null,
"livertox_id": null,
"hepatotoxicity_score": 5
},
"spl_meta": {
"008776cc-83f1-4f8c-819b-6471425da15f": {
"match": "brand_token",
"title": "VABRINTY (LEUPROLIDE ACETATE) INJECTION, SUSPENSION, EXTENDED RELEASE [URONOVA PHARMACEUTICALS, INC.]",
"spl_version": "9",
"published_date": "2026-01-28"
}
},
"productid": "85043-030_b8da8614-75a8-453c-be31-0568da16a3b9",
"productndc": "85043-030",
"dosage_form": "INJECTION, SUSPENSION, EXTENDED RELEASE",
"orange_book": {
"appl_no": "021488",
"products": [
{
"rs": true,
"rld": true,
"te_code": null,
"strength": "30MG",
"product_no": "001",
"approval_date": "Feb 13, 2003"
}
],
"appl_type": "N"
},
"dea_schedule": null,
"product_type": "HUMAN PRESCRIPTION DRUG",
"substance_name": "LEUPROLIDE ACETATE",
"proprietary_name": "Vabrinty",
"active_ingred_unit": "mg/.5mL",
"application_number": "NDA021488",
"marketing_category": "NDA AUTHORIZED GENERIC",
"nonproprietary_name": "Leuprolide acetate",
"start_marketing_date": "20250804",
"active_numerator_strength": "30"
}See everything about leuprorelin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.